Medicines Co's antibiotic succeeds in late-stage trial

Medicines Co's antibiotic succeeds in late-stage trial


The Medicines Co said its experimental antibiotic met the main goals of a late-stage trial on patients with complicated urinary tract infections. The drug, Carbavance , also demonstrated statistical superiority over piperacillin-tazobactam, a combination of existing antibiotic treatments, the company said in a statement.



from Biotech News